BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 773412)

  • 1. The clinical assessment of topical corticosteroid activity.
    Wilson L
    Br J Dermatol; 1976 Mar; 94 suppl 12():33-42. PubMed ID: 773412
    [TBL] [Abstract][Full Text] [Related]  

  • 2. BETAMETHASONE 17-VALERATE: A NEW TOPICAL CORTICOSTEROID.
    WILLIAMS DI; WILKINSON DS; OVERTON J; MILNE JA; MCKENNA WB; LYELL A; CHURCH R
    Lancet; 1964 May; 1(7344):1177-9. PubMed ID: 14132653
    [No Abstract]   [Full Text] [Related]  

  • 3. Topical corticosteroids for skin disorders.
    Med Lett Drugs Ther; 1966 May; 8(10):37-8. PubMed ID: 4223426
    [No Abstract]   [Full Text] [Related]  

  • 4. Tibicorten and betamethasone valerate: a double-blind comparative study.
    Tazelaar DJ
    J Int Med Res; 1977; 5(5):338-45. PubMed ID: 334605
    [TBL] [Abstract][Full Text] [Related]  

  • 5. COMPARATIVE EFFECTS OF CURRENT TOPICAL CORTICOSTEROIDS.
    EDELSTEIN AJ
    Arch Dermatol; 1964 Mar; 89():393-4. PubMed ID: 14096359
    [No Abstract]   [Full Text] [Related]  

  • 6. Comparative double-blind clinical trial of fluocinonide and betamethasone valerate.
    Sarkany I
    Acta Derm Venereol Suppl (Stockh); 1971 May; 52(67):70-1. PubMed ID: 4947904
    [No Abstract]   [Full Text] [Related]  

  • 7. "Metosyn" in psoriasis and eczema.
    Portnoy B; Sarkany I
    Br J Dermatol; 1972 Mar; 86(3):310-1. PubMed ID: 4553161
    [No Abstract]   [Full Text] [Related]  

  • 8. A double-blind controlled trial of betamethasone dipropionate 0.05% (Diproderm) in comparison with fluocinolone acetonide 0.025% (Synalar) in psoriasis and other steroid-responsive dermatoses.
    Afzelius HW; Jacobsen KU
    J Int Med Res; 1979; 7(5):411-4. PubMed ID: 387495
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [TREATMENT OF PSORIASIS WITH WET OCCLUSIVE DRESSING].
    KONIA H
    Dermatologica; 1964; 129():47-56. PubMed ID: 14181377
    [No Abstract]   [Full Text] [Related]  

  • 10. Treatment of localized skin lesions with betamethasone 17-valerate and triamcinolone acetonide in alcoholic solution under occlusive dressing. A double blind comparative study.
    Neering H; van der Kroon HV; Roeleveld CG
    Dermatologica; 1972; 145(6):395-9. PubMed ID: 4571883
    [No Abstract]   [Full Text] [Related]  

  • 11. DOUBLE-BLIND COMPARATIVE TRIAL OF BETAMETHASONE 17-VALERATE AND FLUOCINOLONE ACETONIDE OINTMENTS.
    BUCKLEY DB
    J Ir Med Assoc; 1964 Aug; 55():45-7. PubMed ID: 14179703
    [No Abstract]   [Full Text] [Related]  

  • 12. Onset of the vasoconstrictor effect of diflucortolone valerate, betamethasone valerate, and fluocinolone acetonide ointments applied for varying periods under occlusive dressings.
    Szadurski J; Renz F; Gasser D
    Dermatologica; 1976; 153(4):236-42. PubMed ID: 1017533
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Betamethasone 17-valerate ointment in a lanolin-free base.
    Wilson L
    Curr Med Res Opin; 1973; 1(4):228-32. PubMed ID: 4589630
    [No Abstract]   [Full Text] [Related]  

  • 14. BETAMETHASONE 17-VALERATE: A CLINICAL TRIAL OF A NEW TOPICAL STEROID.
    MITCHELL DM; HEANY SH; EAKINS TS
    J Ir Med Assoc; 1964 Aug; 55():44-5. PubMed ID: 14179702
    [No Abstract]   [Full Text] [Related]  

  • 15. Desonide, a potent nonfluorinated topical steroid, vasoconstriction assay and clinical trial.
    Smith EB; Gregory JF; Bartruff JK
    South Med J; 1973 Mar; 66(3):325-9. PubMed ID: 4570656
    [No Abstract]   [Full Text] [Related]  

  • 16. The clinical evaluation of a new topical corticosteroid, clobetasol propionate. An international controlled trial.
    Sparkes CG; Wilson L
    Br J Dermatol; 1974 Feb; 90(2):197-203. PubMed ID: 4594577
    [No Abstract]   [Full Text] [Related]  

  • 17. Comparison of fluocinonide and betamethasone in the treatment of psoriasis and eczema.
    Portnoy B
    Acta Derm Venereol Suppl (Stockh); 1971 May; 52(67):72-3. PubMed ID: 5291636
    [No Abstract]   [Full Text] [Related]  

  • 18. Newer topical therapy in dermatology.
    Bluefarb SM
    Int J Dermatol; 1970; 9(3):200-8. PubMed ID: 5476381
    [No Abstract]   [Full Text] [Related]  

  • 19. Relative potency of percutaneously absorbed corticosteroids in the suppression of pituitary-adrenal function.
    Scoggins RB; Kliman B
    J Invest Dermatol; 1965 Nov; 45(5):347-55. PubMed ID: 5321337
    [No Abstract]   [Full Text] [Related]  

  • 20. Influence of the base on the results of clinical trials with topical corticosteroids.
    Vollum DI; Sparkes CG
    Dermatologica; 1979; 158(4):293-8. PubMed ID: 372027
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.